PRODUCT INFORMATION



PT2385

Item No. 21325

CAS Registry No.: 1672665-49-4

Formal Name: 3-[[(1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-


7-(methylsulfonyl)-1H-inden-4-yl]oxy]-5-

fluoro-benzonitrile

MF: $C_{17}H_{12}F_3NO_4S$

383.3 FW: ≥98% **Purity:** Supplied as: A solid Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

PT2385 is supplied as a solid. A stock solution may be made by dissolving the PT2385 in the solvent of choice, which should be purged with an inert gas. PT2385 is sparingly soluble (1-10 mg/ml) in DMSO.

Description

PT2385 is an inhibitor of hypoxia-inducible factor- 2α (HIF- 2α ; IC₅₀ = 12 nM).¹ It inhibits HIF- 2α -induced transcription of intratumoral Vegfa mRNA and reduces tumor volume in a 786-O renal cell carcinoma mouse xenograft model when administered at a dose of 10 mg/kg. PT2385 (20 mg/kg) also inhibits the production of soluble FMS-related tyrosine kinase 1 (sFlt1) and prevents the development of hypertension and proteinuria, markers of preeclampsia, in pregnant rat dams.²

References

- 1. Wehn, P.M., Rizzi, J.P., Dixon, D.D., et al. Design and activity of specific hypoxia-inducible factor-2α (HIF-2α) inhibitors for the treatment of clear cell renal cell carcinoma: Discovery of clinical candidate s-3-((2,2difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1h-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). J. Med. Chem. 61(21), 9691-9721 (2018).
- 2. Colson, A., Depoix, C.L., Lambert, I., et al. Specific HIF-2α (hypoxia-inducible factor-2) inhibitor PT2385 mitigates placental dysfunction in vitro and in a rat model of preeclampsia (RUPP). Hypertension 80(5), 1011-1023 (2023).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 06/24/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM